Related Experiment Video
Updated: Jun 5, 2025
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
Monoclonal Gammopathy-Associated Neuropathy
Shayna Sarosiek1,2, Christopher T Doughty3,4, Jorge J Castillo5,4
1Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute450 Brookline Ave, Mayer 223, Boston, MA, 02215, USA. Shayna_sarosiek@dfci.harvard.edu.
Purpose Of Review:
Peripheral neuropathy (PN) is more commonly seen in individuals with monoclonal gammopathies, especially in patients with an IgM monoclonal gammopathy or Waldenström macroglobulinemia.
Recent Findings:
There are multiple potential ways that the paraprotein may result in peripheral neuropathy. The diagnosis and management of monoclonal gammopathy-associated PN are challenging and necessitate a concerted effort between the hematologist/oncologist and the neurologist. This review describes the most common PN syndromes associated with monoclonal gammopathy, such as anti-myelin-associated glycoprotein neuropathy, light chain amyloidosis, cryoglobulinemia, POEMS, CANOMAD, and others. We also review the therapies used to treat these conditions.
Insights
Peripheral neuropathy (PN) is frequently linked to monoclonal gammopathies, particularly IgM monoclonal gammopathy or Waldenström macroglobulinemia. This review details common PN syndromes and their treatments.
Area of Science:
- Neurology
- Hematology
- Oncology
Background:
- Peripheral neuropathy (PN) is a known complication of monoclonal gammopathies.
- Individuals with IgM monoclonal gammopathy or Waldenström macroglobulinemia have a higher incidence of PN.
Purpose of the Study:
- To review common PN syndromes associated with monoclonal gammopathies.
- To discuss the diagnosis and management of these complex conditions.
- To outline current therapeutic strategies for monoclonal gammopathy-associated PN.
Main Methods:
- Literature review of common PN syndromes in monoclonal gammopathy patients.
- Analysis of diagnostic challenges and management approaches.
- Synthesis of information on therapeutic interventions.
Main Results:
- Monoclonal gammopathies, especially IgM types, are strongly associated with PN.
- Several PN syndromes are linked to paraprotein deposition or immune mechanisms.
- Effective management requires collaboration between hematologists/oncologists and neurologists.
Conclusions:
- Understanding the diverse PN syndromes associated with monoclonal gammopathies is crucial.
- Timely diagnosis and multidisciplinary management improve patient outcomes.
- Current therapies offer options for treating these challenging neurological conditions.
More Related Videos
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
07:30A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
